What drove the SANN.SW stock drop today?

The **SANN.SW stock** fell **5.83%** on heavier volume (**133,735.00**) and a gap lower from **CHF15.40**. Selling hit near the 50-day average and momentum indicators weakened, adding technical pressure to the shares

What is Meyka AI's price forecast for SANN.SW stock?

Meyka AI's forecast model projects a **yearly** price of **CHF16.49**, implying **13.42%** upside from the current **CHF14.54**. Forecasts are model-based projections and not guarantees

Is SANN.SW stock a buy based on fundamentals?

Fundamentals show negative EPS (**-5.34**) and negative operating cash flow per share (**-3.20**). Meyka grades SANN.SW **B+** (BUY) on balanced factors, but investors must weigh pipeline upside against cash burn and clinical risk

What near-term events could move SANN.SW stock?

The next earnings announcement on **28 Apr 2026** and any clinical updates on vamorolone or lonodelestat are primary catalysts. Regulatory or out‑licensing news can also swing the share price materially

CH Stocks

SANN.SW -5.83% to CHF14.54 on 16 Mar 2026: model flags 13.42% upside

ByDanny Kontos March 17, 2026

The SANN.SW stock closed down 5.83% at CHF14.54 on SIX on 16 Mar 2026, marking one of the session’s largest declines. Trading volume of 133,735.00 shares exceeded the average of 109,984.00, signaling heavier selling pressure. The drop followed a gap lower from an open at CHF15.40 and left the share price nearer the day low of CHF14.30. Below we analyse what pushed the move, how fundamentals stack up, and what our models project next for Santhera Pharmaceuticals Holding AG (SANN.SW)